Davion Healthcare is an early-stage Irish medical device company developing non-invasive home health screening tests based on thermochromic liquid crystal film — a thin material that produces visible color changes in response to skin surface temperature. Users apply the film to their skin, photograph it with a smartphone, and submit the image to Davion's AI-powered portal, which returns a result within minutes. Davion's lead product, BreastCheck, detects abnormal breast tissue temperature patterns and is positioned as a low-cost, over-the-counter first-line screening tool — not a mammogram replacement. A second product, FootFlow, monitors foot circulation for diabetics and patients at risk for Peripheral Arterial Disease. Two additional products, Testic and ThermaDerm, are in the pipeline. All four are classified as Class I (low-risk, non-diagnostic) devices in the U.S., EU, and UK, allowing over-the-counter sale without premarket regulatory approval. Davion operates as a pure IP licensing business — it develops and patents products, then licenses manufacturing and distribution rights to partners in exchange for upfront license fees and ongoing royalties. Davion's only signed deal is with NeuRX Health, which holds global rights to BreastCheck and owes Davion $120M in staged fees plus minimum annual royalties of $10M per year over a 10-year term. Davion has no revenue yet; BreastCheck's U.S. launch is targeted for the second half of 2026. Davion owns no equipment or property, and licensees bear all manufacturing, marketing, and distribution costs.